DENV3 Antibody CDR Engineering for High Neutralization Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-DENV3 antibodies exhibit insufficient binding affinity and neutralization activity, and there is a need for improved antibodies suitable for preventing or treating dengue disease, particularly for seronegative populations, while avoiding cross-reactivity with Zika virus.
Innovation Solution
Development of anti-DENV3 antibodies with specific VH and VL CDR regions, characterized by high binding activity, neutralization activity, and low dissociation rates, with minimal cross-reactivity to Zika virus, using clones such as 8D4, 12H6, 5D7, and 13E10, which are engineered for enhanced specificity and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If commercially available anti-DENV3 antibodies are used, then they are available for immediate use, but they exhibit insufficient binding affinity and neutralization activity
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequences of the antibody's CDR regions (VH CDR1-3 and VL CDR1-3) to optimize binding affinity and neutralization activity. Specific sequence variations are introduced to enhance the antibody's ability to bind DENV3 with IC50 ≤ 15 nM and neutralize virus particles with EC50 ≤ 60 ng/ml, directly resolving the insufficiency of commercially available antibodies.
Solution Approach 2:
The patent applies local quality by focusing improvements on specific regions of the antibody molecule - the complementarity determining regions (CDRs). By optimizing the amino acid sequences in these local regions (VH CDR1-3 and VL CDR1-3) while maintaining other parts of the antibody structure, the invention enhances binding and neutralization properties without requiring complete redesign of the entire antibody molecule.
2Reliability
If antibodies with high binding affinity are developed, then neutralization activity improves, but development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the antibody molecule into distinct functional regions - specifically identifying and optimizing the five CDR regions (VH CDR1-3 and VL CDR1-3) separately. This segmentation allows focused engineering of binding and neutralization properties in these specific regions while using standardized framework regions, thereby managing development complexity through modular design.
Solution Approach 2:
The patent applies universality by designing antibody variants that maintain multiple functions simultaneously - binding to DENV3, neutralizing viral particles, and exhibiting low dissociation rates (koff ≤ 1×10^-4 sec^-1). The optimized CDR sequences are designed to fulfill multiple functional requirements in a single antibody molecule, reducing the need for separate engineering efforts for each function.
3Object-affected harmful factors
If antibodies are designed for high specificity to DENV3, then cross-reactivity with Zika virus decreases, but design precision requirements increase
Solution Approach 1:
The patent applies local quality by introducing specific amino acid variations in the CDR regions that confer DENV3 specificity while minimizing cross-reactivity with Zika virus. These localized sequence changes in VH CDR1-3 and VL CDR1-3 create epitope recognition patterns that are highly specific to DENV3 antigens, achieving cross-reactivity reduction through precise local modifications rather than global sequence changes.
Solution Approach 2:
The patent applies parameter changes by establishing specific sequence identity thresholds (≥85% identity for VH CDR1-3 and ≥82% for VL CDR1-3) that balance manufacturing feasibility with functional specificity. These parameter definitions provide clear design criteria that guide antibody engineering while ensuring the required level of DENV3 specificity and minimal Zika cross-reactivity.
Data Source
AI summary
The present invention relates to anti-dengue virus serotype 3 (DENV3) antibodies and antigen binding fragments thereof. Further, nucleic acids encoding them and host cells comprising them are provided. In addition, the use of the antibodies in the prevention or treatment of dengue disease is provided. Also, diagnostic methods using them and kits comprising them are provided.